Talks of an additional trial for the parathyroid hormone nasal spray (PTH1-34) to treat osteoporosis led Nastech Pharmaceutical Co. Inc. and Procter & Gamble Pharmaceuticals Inc. to amend their 10-month-old agreement - meaning Nastech will not receive $15 million in milestone payments this year as expected. (BioWorld Today)